LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Home・Stock List・TG Therapeutics Inc

TG Therapeutics Inc

Open

Sector Healthcare

24.11 -10

Buy Sell

Overview

Share price change

24h

Current

Min

22.86

Max

26.79

Key metrics
By Trading Economics
Income	18M 6.9M
Sales	10M 73M
EPS	0.04
Profit margin	9.364
Employees	264
EBITDA	-8.3M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+42.49 upside

Dividends
By Dow Jones
Next Earnings	4 Nov 2024

Market Stats
By TradingEconomics
Market Cap	97M 3.9B
Previous open	34.11
Previous close	24.11

News Sentiment

By Acuity

25%

75%

59 / 390 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

24.37 / N/A Support & Resistance

TG Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 Aug 2024, 20:01 UTC

Earnings

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Peer Comparison

Price change

TG Therapeutics Inc Forecast

Price Target

By TipRanks

42.49% upside

12 Months Forecast

Average 38.33 USD 42.49%

High 50 USD

Low 20 USD

Based on 6 Wall Street analysts offering 12 month price targets forTG Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to TG Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

24.37 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

59 / 390 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About TG Therapeutics Inc

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).